1.Measured by its binding ability in a functional ELISA. Immobilized human CD112 at 10 μg/ml (100 μl/well) can bind human DNAM1-Fch with a linear range of 1.25-10 μg/ml. 2.Loaded Human PVRIG Protein, mFc Tag on AMC Biosensor, can bind Human Nectin-2 protein with an affinity constant of 0.680μM as determined in BLI assay (Routinely tested).

Nectin-2 Protein, Human, Recombinant is expressed in HEK293 mammalian cells. The predicted molecular weight is 36.2 kDa and the accession number is Q92692-2.

Human

HEK293 Cells

PRR2,Nectin-2,PVRR2,poliovirus receptor-related 2 (herpesvirus entry mediator B),HVEB,CD112

The mature form of recombinant Human CD112 (NP_002847.1) extracellular domain (Met 1-Leu 360) with quinary-aa peptide (DDDDK) at the C-terminus was expressed and purified.

≥ 95 % as determined by SDS-PAGE. ≥ 90 % as determined by SEC-HPLC.

A Certificate of Analysis (CoA) containing reconstitution instructions is included with the products. Please refer to the CoA for detailed information.

It is recommended to store recombinant proteins at -20°C to -80°C for future use. Lyophilized powders can be stably stored for over 12 months, while liquid products can be stored for 6-12 months at -80°C. For reconstituted protein solutions, the solution can be stored at -20°C to -80°C for at least 3 months. Please avoid multiple freeze-thaw cycles and store products in aliquots.

Cluster of Differentiation 112 (CD112), also known as poliovirus receptor related protein 2 (PVRL2 or PRR2), is a single-pass type I transmembrane glycoprotein belonging to the Immunoglobulin superfamily. CD112 protein also serves as an entry for certain mutant strains of herpes simplex virus and pseudorabies virus, and thus is involved in cell to cell spreading of these viruses. CD112 protein has been identified as the ligand for DNAM-1 (CD226), and the interaction of CD226/CD112 protein can induce NK cell- and CD8+T cell-mediated cytotoxicity and cytokine secretion. CD112 has been regarded as a critical component in allergic reactions, and accordingly may function as a novel target for anti-allergic therapy.